WO2003054152A3 - Novel nucleic acids and polypeptides - Google Patents

Novel nucleic acids and polypeptides Download PDF

Info

Publication number
WO2003054152A3
WO2003054152A3 PCT/US2002/039555 US0239555W WO03054152A3 WO 2003054152 A3 WO2003054152 A3 WO 2003054152A3 US 0239555 W US0239555 W US 0239555W WO 03054152 A3 WO03054152 A3 WO 03054152A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acids
polypeptides
novel nucleic
novel
present
Prior art date
Application number
PCT/US2002/039555
Other languages
French (fr)
Other versions
WO2003054152A2 (en
Inventor
Y Tom Tang
Vinod Asundi
Ryle W Goodrich
Feiyan Ren
Jie Zhang
Qing A Zhao
Jian-Rui Wang
Malabika Ghosh
Aidong J Xue
Tom Wehrman
Gezhi Weng
Ping Zhou
Radoje T Drmanac
Zhiwei Wang
Yunqing Ma
Dunrui Wang
Rui-Hong Chen
Chongjun Xu
Bryan J Boyle
Original Assignee
Nuvelo Inc
Y Tom Tang
Vinod Asundi
Ryle W Goodrich
Feiyan Ren
Jie Zhang
Qing A Zhao
Jian-Rui Wang
Malabika Ghosh
Aidong J Xue
Tom Wehrman
Gezhi Weng
Ping Zhou
Radoje T Drmanac
Zhiwei Wang
Yunqing Ma
Dunrui Wang
Rui-Hong Chen
Chongjun Xu
Bryan J Boyle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/128,558 external-priority patent/US20040219521A1/en
Application filed by Nuvelo Inc, Y Tom Tang, Vinod Asundi, Ryle W Goodrich, Feiyan Ren, Jie Zhang, Qing A Zhao, Jian-Rui Wang, Malabika Ghosh, Aidong J Xue, Tom Wehrman, Gezhi Weng, Ping Zhou, Radoje T Drmanac, Zhiwei Wang, Yunqing Ma, Dunrui Wang, Rui-Hong Chen, Chongjun Xu, Bryan J Boyle filed Critical Nuvelo Inc
Priority to CA002469941A priority Critical patent/CA2469941A1/en
Priority to EP02805571A priority patent/EP1504099A4/en
Priority to AU2002366951A priority patent/AU2002366951A1/en
Publication of WO2003054152A2 publication Critical patent/WO2003054152A2/en
Publication of WO2003054152A3 publication Critical patent/WO2003054152A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.
PCT/US2002/039555 2001-12-10 2002-12-10 Novel nucleic acids and polypeptides WO2003054152A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002469941A CA2469941A1 (en) 2001-12-10 2002-12-10 Novel nucleic acids and polypeptides
EP02805571A EP1504099A4 (en) 2001-12-10 2002-12-10 Novel nucleic acids and polypeptides
AU2002366951A AU2002366951A1 (en) 2001-12-10 2002-12-10 Novel nucleic acids and polypeptides

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US33973901P 2001-12-10 2001-12-10
US60/339,739 2001-12-10
US33945301P 2001-12-11 2001-12-11
US60/339,453 2001-12-11
US36538402P 2002-03-14 2002-03-14
US36509102P 2002-03-14 2002-03-14
US60/365,384 2002-03-14
US60/365,091 2002-03-14
US37238102P 2002-04-12 2002-04-12
US37261502P 2002-04-12 2002-04-12
US60/372,381 2002-04-12
US60/372,615 2002-04-12
US10/128,558 2002-04-22
US10/128,558 US20040219521A1 (en) 2000-01-21 2002-04-22 Novel nucleic acids and polypeptides
US37604502P 2002-04-24 2002-04-24
US60/376,045 2002-04-24

Publications (2)

Publication Number Publication Date
WO2003054152A2 WO2003054152A2 (en) 2003-07-03
WO2003054152A3 true WO2003054152A3 (en) 2004-12-16

Family

ID=27574889

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/039555 WO2003054152A2 (en) 2001-12-10 2002-12-10 Novel nucleic acids and polypeptides

Country Status (4)

Country Link
EP (1) EP1504099A4 (en)
AU (1) AU2002366951A1 (en)
CA (1) CA2469941A1 (en)
WO (1) WO2003054152A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932821B2 (en) 2003-03-19 2015-01-13 Biogen Idec Ma Inc. NOGO receptor binding protein
US9394330B2 (en) 2012-03-21 2016-07-19 Alios Biopharma, Inc. Solid forms of a thiophosphoramidate nucleotide prodrug
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9315698U1 (en) * 1993-10-14 1993-12-23 Buechi Lab Tech Evaporator flask for a rotary evaporator
EP1434783A4 (en) * 2001-03-16 2006-06-07 Lilly Co Eli Lp mammalian proteins; related reagents
EP1992643A3 (en) 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20030068691A1 (en) * 2001-07-16 2003-04-10 Applera Corporation Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
JP4208715B2 (en) * 2001-08-30 2009-01-14 ヌヴェロ， インコーポレイテッド Methods and materials for stem cell growth factor-like polypeptides and polynucleotides
CA2462790A1 (en) 2001-10-04 2003-04-10 Immunex Corporation Ul16 binding protein 4
US7202056B2 (en) 2002-03-28 2007-04-10 Bristol-Myers Squibb Company Polynucleotides encoding a human cell surface protein with immunoglobulin folds, BGS-19
WO2003091436A1 (en) 2002-04-26 2003-11-06 Fujisawa Pharmaceutical Co., Ltd. Novel 35 kd protein
WO2004005335A2 (en) * 2002-07-05 2004-01-15 Borean Pharma A/S Multimerised growth hormone fusion proteins
JP5401001B2 (en) 2002-09-11 2014-01-29 ジェネンテック， インコーポレイテッド Novel compositions and methods for the treatment of immune related diseases
JP4679149B2 (en) 2002-09-30 2011-04-27 オンコセラピー・サイエンス株式会社 Genes and polypeptides related to human pancreatic cancer
JP4632953B2 (en) * 2003-09-29 2011-02-16 中外製薬株式会社 Protein expressed in NK cells
ATE423200T1 (en) * 2003-10-30 2009-03-15 Kazusa Dna Res Inst Foundation NEW PLEXIN POLYPEPTIDE, DNA CODING IT AND USE THEREOF
KR101520209B1 (en) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. Monomethylvaline compounds capable of conjugation to ligands
TW200536859A (en) * 2004-01-27 2005-11-16 Nuvelo Inc Gastrointestinal proliferative factor and uses thereof
GB0403491D0 (en) * 2004-02-17 2004-03-24 Univ Cambridge Tech Polypeptides, methods and means
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
ATE491043T1 (en) * 2004-04-09 2010-12-15 Us Gov Health & Human Serv DIAGNOSTIC DEVICE FOR DIAGNOSIS OF BENEFITS VERSUS MALIGNANT THYROID LESIONS
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
ES2395094T3 (en) 2004-06-24 2013-02-08 Biogen Idec Ma Inc. Treatment of conditions that involve demyelination
WO2006008294A2 (en) * 2004-07-23 2006-01-26 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of slim3 for neurodegenerative diseases
EP1791565B1 (en) 2004-09-23 2016-04-20 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
WO2006124667A2 (en) 2005-05-12 2006-11-23 Zymogenetics, Inc. Compositions and methods for modulating immune responses
MX2008000253A (en) 2005-07-08 2008-04-02 Biogen Idec Inc Sp35 antibodies and uses thereof.
ES2543341T3 (en) 2005-09-13 2015-08-18 National Research Council Of Canada Methods and compositions to modulate the activity of tumor cells
GB0522113D0 (en) * 2005-10-28 2005-12-07 Ares Trading Sa vWFA-domain containing proteins
GB0525999D0 (en) * 2005-12-21 2006-02-01 Ares Trading Sa Novel members of the kazal family of serine protease inhibitors
GB0615287D0 (en) * 2006-08-01 2006-09-06 Ares Trading Sa Integral membrane protein
CA2665223A1 (en) * 2006-10-02 2008-05-29 The Scripps Research Institute An enzyme regulating ether lipid signaling pathways
GB0620735D0 (en) * 2006-10-18 2006-11-29 Ares Trading Sa Proteins
CA2691378A1 (en) 2007-07-02 2009-01-08 Oncomed Pharmaceuticals, Inc. Antibody against human r-spondin (rspo) and use thereof for inhibition of beta-catenin signaling and treatment of cancer
GB0805159D0 (en) 2008-03-19 2008-04-23 Sancho Madrid David Immune modulation via C-type lectin
CA2697448C (en) 2007-08-30 2019-06-11 The Burnet Institute Dendritic cell marker and uses thereof
WO2009046407A2 (en) * 2007-10-04 2009-04-09 Zymogenetics, Inc. B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS
CN101918540B (en) * 2007-11-08 2016-05-11 比奥根Ma公司 LINGO-4 antagonist relates to the application in the illness of demyelinate in treatment
SG10201402815VA (en) 2008-04-09 2014-09-26 Genentech Inc Novel compositions and methods for the treatment of immune related diseases
US20110110861A1 (en) * 2008-05-13 2011-05-12 Mireille Hanna Lahoud Methods of Detecting Cells with a Disrupted Cell Membrane, Cells Infected with A Pathogen, Dying Cells or Dead Cells
DK2982695T3 (en) 2008-07-09 2019-05-13 Biogen Ma Inc COMPOSITIONS CONCERNING ANTIBODIES AGAINST LINGO OR FRAGMENTS THEREOF
US8227417B2 (en) 2008-07-25 2012-07-24 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
PL3441458T3 (en) 2009-02-03 2023-11-06 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising said stem cells
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
EP2448966B1 (en) 2009-07-03 2018-11-14 Avipep Pty Ltd Immuno-conjugates and methods for producing them
WO2011004404A1 (en) * 2009-07-10 2011-01-13 Decode Genetics Ehf Genetic variants for predicting risk of glaucoma
JP2013504585A (en) 2009-09-09 2013-02-07 セントローズ， エルエルシー Extracellular targeted drug complex
ES2734886T3 (en) 2009-11-24 2019-12-12 Alethia Biotherapeutics Inc Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
CA2784610C (en) 2009-12-23 2020-07-14 Avipep Pty Ltd Immuno-conjugates and methods for producing them
KR101738203B1 (en) 2010-04-15 2017-05-19 메디뮨 리미티드 Pyrrolobenzodiazepines and conjugates thereof
CA3220104A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
NZ607996A (en) 2010-09-22 2014-07-25 Alios Biopharma Inc Substituted nucleotide analogs
US20120121615A1 (en) 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
WO2012142662A1 (en) 2011-04-21 2012-10-26 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using them b
JP5987053B2 (en) 2011-05-12 2016-09-06 ジェネンテック， インコーポレイテッド Multiple reaction monitoring LC-MS / MS method for detecting therapeutic antibodies in animal samples using framework signature peptides
WO2013012747A1 (en) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
EP2750713B1 (en) 2011-10-14 2015-09-16 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc Substituted phosphorothioate nucleotide analogs
CN104159611A (en) 2012-02-22 2014-11-19 阿莱斯亚生物疗法股份有限公司 Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
WO2013173364A2 (en) 2012-05-14 2013-11-21 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
JP6335896B2 (en) 2012-07-13 2018-05-30 オンコメッド ファーマシューティカルズ インコーポレイテッド RSPO3 binding agent and method of use thereof
SI2906253T1 (en) 2012-10-12 2018-11-30 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
WO2014057120A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
HUE045435T2 (en) 2012-10-12 2019-12-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
HUE042731T2 (en) 2012-10-12 2019-07-29 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
ES2680153T3 (en) 2012-10-12 2018-09-04 Adc Therapeutics Sa Anti-PSMA-pyrrolobenzodiazepine antibody conjugates
BR112015008238A2 (en) 2012-10-12 2017-11-28 Adc Therapeutics Sarl pyrrolbenzodiazepine-anti-cd22 antibody conjugates
AU2013328625B2 (en) 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
JP6340019B2 (en) 2013-03-13 2018-06-06 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugates
EA027910B1 (en) 2013-03-13 2017-09-29 Медимьюн Лимитед Pyrrolobenzodiazepines and conjugates thereof
KR20160030936A (en) 2013-07-16 2016-03-21 제넨테크, 인크. Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
MX2016001862A (en) 2013-08-12 2016-08-03 Genentech Inc 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment.
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
JP6980384B2 (en) 2013-12-16 2021-12-15 ジェネンテック， インコーポレイテッド 1- (Chloromethyl) -2,3-dihydro-1H-benzo [E] indole dimer antibody-drug conjugate compound, and methods of use and treatment
RU2689388C1 (en) 2013-12-16 2019-05-28 Дженентек, Инк. Peptidomimetic compounds and their conjugates of antibodies with drugs
EP3082875B1 (en) 2013-12-16 2020-11-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CA2957354A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3191134B1 (en) 2014-09-12 2019-11-20 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
US10064937B2 (en) 2014-09-16 2018-09-04 Oncomed Pharmaceuticals, Inc. Treatment of dermal fibrosis
MX2017003523A (en) 2014-09-17 2017-11-08 Genentech Inc Pyrrolobenzodiazepines and antibody disulfide conjugates thereof.
CN107148285B (en) 2014-11-25 2022-01-04 Adc治疗股份有限公司 Pyrrolobenzodiazepine-antibody conjugates
EP3226909A1 (en) 2014-12-03 2017-10-11 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
MX2017009038A (en) 2015-01-08 2017-10-25 Biogen Ma Inc Lingo-1 antagonists and uses for treatment of demyelinating disorders.
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
CR20220186A (en) 2015-09-25 2022-07-07 Genentech Inc Anti-tigit antibodies and methods of use
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP6943872B2 (en) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド Multiple whole antibody and antibody complex drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
JP7022080B2 (en) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド Biochemical analytical methods for the characterization of site-specific antibody-drug conjugates
EP3464280B1 (en) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
CN110139674B (en) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 Method for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
WO2018115879A1 (en) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
JP6671555B2 (en) 2017-02-08 2020-03-25 アーデーセー セラピューティクス ソシエテ アノニム Pyrrolobenzodiazepine antibody conjugate
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
AU2018255876B2 (en) 2017-04-18 2020-04-30 Medimmune Limited Pyrrolobenzodiazepine conjugates
AU2018253948A1 (en) 2017-04-20 2019-09-19 Adc Therapeutics Sa Combination therapy with an anti-AXL Antibody-Drug Conjugate
MX2019015042A (en) 2017-06-14 2020-08-06 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc.
KR102270107B1 (en) 2017-08-18 2021-06-30 메디뮨 리미티드 pyrrolobenzodiazepine conjugate
CN111788208B (en) 2017-09-20 2023-11-24 Ph制药有限公司 Talarstatin analogues
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US11401339B2 (en) 2018-08-23 2022-08-02 Seagen Inc. Anti-TIGIT antibodies
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
JP2022505450A (en) 2018-10-24 2022-01-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Conjugated chemical decomposition inducers and usage
CN113227119A (en) 2018-12-10 2021-08-06 基因泰克公司 Photocrosslinked peptides for site-specific conjugation to Fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
GB202211117D0 (en) * 2022-07-29 2022-09-14 Replay Holdings Llc Compositions and methods for non-immunogenecity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP1504099A4 *
VOLLRATH D. ET AL: "The human Y chromosome: a 43-interval map based on naturally occurring deletions", SCIENCE, vol. 258, October 1992 (1992-10-01), pages 52 - 59, XP002940166 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932821B2 (en) 2003-03-19 2015-01-13 Biogen Idec Ma Inc. NOGO receptor binding protein
US9394330B2 (en) 2012-03-21 2016-07-19 Alios Biopharma, Inc. Solid forms of a thiophosphoramidate nucleotide prodrug
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Also Published As

Publication number Publication date
WO2003054152A2 (en) 2003-07-03
CA2469941A1 (en) 2003-07-03
EP1504099A2 (en) 2005-02-09
AU2002366951A1 (en) 2003-07-09
EP1504099A4 (en) 2006-05-10

Similar Documents

Publication Publication Date Title
WO2003054152A3 (en) Novel nucleic acids and polypeptides
WO2003025148A3 (en) Novel nucleic acids and polypeptides
WO2002070539A3 (en) Novel nucleic acids and polypeptides
WO2003023013A3 (en) Novel nucleic acids and polypeptides
WO2002081731A3 (en) Novel nucleic acids and polypeptides
WO2001075067A3 (en) Novel nucleic acids and polypeptides
WO2001057188A3 (en) Novel nucleic acids and polypeptides
WO2001057190A3 (en) Novel nucleic acids and polypeptides
WO2002022660A3 (en) Novel nucleic acids and polypeptides
WO2001066689A3 (en) Novel nucleic acids and polypeptides
WO2002031111A3 (en) Novel nucleic acids and polypeptides
WO2001088088A3 (en) Novel nucleic acids and polypeptides
WO2004009834A3 (en) Novel nucleic acids and secreted polypeptides
WO2002059260A3 (en) Nucleic acids and polypeptides
WO2001053312A8 (en) Novel nucleic acids and polypeptides
WO2001053455A3 (en) Novel nucleic acids and polypeptides
WO2004080148A3 (en) Novel nucleic acids and polypeptides
WO2003029271A3 (en) Novel nucleic acids and polypeptides
WO2004087874A3 (en) Novel nucleic acids and polypeptides
WO2002018424A3 (en) Nucleic acids and polypeptides
WO2001079449A3 (en) Novel nucleic acids and polypeptides
WO2003080795A3 (en) Novel nucleic acids and secreted polypeptides
WO2002081517A3 (en) Novel polypeptides and nucleic acids encoded thereby
WO2005049806A3 (en) Novel nucleic acids and polypeptides
WO2001075068A3 (en) Secreted proteins and polynucleotides encoding them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002805571

Country of ref document: EP

Ref document number: 2469941

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002366951

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2002805571

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2002805571

Country of ref document: EP